vs
Side-by-side financial comparison of CytomX Therapeutics, Inc. (CTMX) and RED RIVER BANCSHARES INC (RRBI). Click either name above to swap in a different company.
RED RIVER BANCSHARES INC is the larger business by last-quarter revenue ($33.2M vs $18.7M, roughly 1.8× CytomX Therapeutics, Inc.). RED RIVER BANCSHARES INC runs the higher net margin — 34.4% vs -0.8%, a 35.2% gap on every dollar of revenue. On growth, RED RIVER BANCSHARES INC posted the faster year-over-year revenue change (15.7% vs -25.7%). RED RIVER BANCSHARES INC produced more free cash flow last quarter ($42.2M vs $-15.8M). Over the past eight quarters, RED RIVER BANCSHARES INC's revenue compounded faster (12.4% CAGR vs -15.9%).
CytomX Therapeutics is a clinical-stage biotechnology company specializing in innovative cancer immunotherapies. It leverages its proprietary Probody technology platform to develop targeted therapies that activate exclusively in tumor microenvironments, minimizing off-target toxicities, with a pipeline covering multiple solid tumor indications and partnerships with leading global pharmaceutical firms.
Red River Bancshares Inc is a U.S. regional financial holding company operating through its wholly owned subsidiary Red River Bank. It provides a full suite of retail and commercial banking products including deposit accounts, personal and commercial loans, mortgage services, and wealth management, primarily serving customers across Louisiana, with a focus on local communities and small to mid-sized enterprises.
CTMX vs RRBI — Head-to-Head
Income Statement — Q2 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.7M | $33.2M |
| Net Profit | $-154.0K | $11.4M |
| Gross Margin | — | — |
| Operating Margin | -6.9% | 42.8% |
| Net Margin | -0.8% | 34.4% |
| Revenue YoY | -25.7% | 15.7% |
| Net Profit YoY | 97.6% | 22.7% |
| EPS (diluted) | — | $1.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | — | $33.2M | ||
| Q3 25 | — | $31.9M | ||
| Q2 25 | $18.7M | $30.5M | ||
| Q1 25 | $50.9M | $29.9M | ||
| Q4 24 | $38.1M | $28.7M | ||
| Q3 24 | $33.4M | $27.9M | ||
| Q2 24 | $25.1M | $26.9M | ||
| Q1 24 | $41.5M | $26.3M |
| Q4 25 | — | $11.4M | ||
| Q3 25 | — | $10.8M | ||
| Q2 25 | $-154.0K | $10.2M | ||
| Q1 25 | $23.5M | $10.4M | ||
| Q4 24 | $18.9M | $9.3M | ||
| Q3 24 | $5.7M | $8.8M | ||
| Q2 24 | $-6.5M | $8.0M | ||
| Q1 24 | $13.8M | $8.2M |
| Q4 25 | — | 42.8% | ||
| Q3 25 | — | 41.9% | ||
| Q2 25 | -6.9% | 41.7% | ||
| Q1 25 | 44.4% | 43.0% | ||
| Q4 24 | 46.4% | 40.2% | ||
| Q3 24 | 12.3% | 38.8% | ||
| Q2 24 | -33.7% | 36.8% | ||
| Q1 24 | 28.1% | 38.5% |
| Q4 25 | — | 34.4% | ||
| Q3 25 | — | 33.8% | ||
| Q2 25 | -0.8% | 33.4% | ||
| Q1 25 | 46.2% | 34.6% | ||
| Q4 24 | 49.6% | 32.4% | ||
| Q3 24 | 17.2% | 31.4% | ||
| Q2 24 | -26.0% | 29.7% | ||
| Q1 24 | 33.3% | 31.1% |
| Q4 25 | — | $1.72 | ||
| Q3 25 | — | $1.63 | ||
| Q2 25 | — | $1.51 | ||
| Q1 25 | — | $1.52 | ||
| Q4 24 | — | $1.36 | ||
| Q3 24 | — | $1.27 | ||
| Q2 24 | — | $1.16 | ||
| Q1 24 | — | $1.16 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $49.0M | $213.4M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $119.9M | $365.1M |
| Total Assets | $175.1M | $3.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $213.4M | ||
| Q3 25 | — | $161.1M | ||
| Q2 25 | $49.0M | $210.4M | ||
| Q1 25 | $47.6M | $252.2M | ||
| Q4 24 | $38.1M | $269.0M | ||
| Q3 24 | $40.6M | $232.6M | ||
| Q2 24 | $43.2M | $213.1M | ||
| Q1 24 | $36.2M | $229.8M |
| Q4 25 | — | $365.1M | ||
| Q3 25 | — | $351.3M | ||
| Q2 25 | $119.9M | $335.4M | ||
| Q1 25 | $25.0M | $333.3M | ||
| Q4 24 | $-456.0K | $319.7M | ||
| Q3 24 | $-23.5M | $324.3M | ||
| Q2 24 | $-31.2M | $307.0M | ||
| Q1 24 | $-31.7M | $299.3M |
| Q4 25 | — | $3.4B | ||
| Q3 25 | — | $3.2B | ||
| Q2 25 | $175.1M | $3.2B | ||
| Q1 25 | $98.5M | $3.2B | ||
| Q4 24 | $120.5M | $3.1B | ||
| Q3 24 | $139.0M | $3.1B | ||
| Q2 24 | $159.2M | $3.0B | ||
| Q1 24 | $184.7M | $3.1B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | $44.8M |
| Free Cash FlowOCF − Capex | $-15.8M | $42.2M |
| FCF MarginFCF / Revenue | -84.6% | 127.2% |
| Capex IntensityCapex / Revenue | 0.1% | 7.8% |
| Cash ConversionOCF / Net Profit | — | 3.92× |
| TTM Free Cash FlowTrailing 4 quarters | $-77.7M | $75.2M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | — | $44.8M | ||
| Q3 25 | — | $16.5M | ||
| Q2 25 | $-15.8M | $3.8M | ||
| Q1 25 | $-21.0M | $13.9M | ||
| Q4 24 | $-19.9M | $38.3M | ||
| Q3 24 | $-20.7M | $17.4M | ||
| Q2 24 | $-19.5M | $2.4M | ||
| Q1 24 | $-26.0M | $14.4M |
| Q4 25 | — | $42.2M | ||
| Q3 25 | — | $15.8M | ||
| Q2 25 | $-15.8M | $3.5M | ||
| Q1 25 | $-21.2M | $13.7M | ||
| Q4 24 | $-20.0M | $33.4M | ||
| Q3 24 | $-20.7M | $17.0M | ||
| Q2 24 | $-19.6M | $1.4M | ||
| Q1 24 | $-26.2M | $13.4M |
| Q4 25 | — | 127.2% | ||
| Q3 25 | — | 49.6% | ||
| Q2 25 | -84.6% | 11.6% | ||
| Q1 25 | -41.6% | 45.7% | ||
| Q4 24 | -52.5% | 116.5% | ||
| Q3 24 | -62.1% | 60.9% | ||
| Q2 24 | -78.2% | 5.4% | ||
| Q1 24 | -63.1% | 50.8% |
| Q4 25 | — | 7.8% | ||
| Q3 25 | — | 2.1% | ||
| Q2 25 | 0.1% | 0.9% | ||
| Q1 25 | 0.2% | 0.9% | ||
| Q4 24 | 0.2% | 17.0% | ||
| Q3 24 | 0.1% | 1.4% | ||
| Q2 24 | 0.4% | 3.6% | ||
| Q1 24 | 0.3% | 4.0% |
| Q4 25 | — | 3.92× | ||
| Q3 25 | — | 1.53× | ||
| Q2 25 | — | 0.37× | ||
| Q1 25 | -0.89× | 1.34× | ||
| Q4 24 | -1.05× | 4.11× | ||
| Q3 24 | -3.61× | 1.99× | ||
| Q2 24 | — | 0.30× | ||
| Q1 24 | -1.89× | 1.76× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
CTMX
| Bristol Myers Squibb Company | $11.6M | 62% |
| Astellas Pharma Inc | $4.6M | 25% |
| Regeneron Pharmaceuticals Inc | $2.1M | 11% |
RRBI
Segment breakdown not available.
